Engineered Therapeutic Antibody Against SARS-CoV-2
| dc.contributor.author | Chulanetra M. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2023-11-21T18:02:06Z | |
| dc.date.available | 2023-11-21T18:02:06Z | |
| dc.date.issued | 2023-01-01 | |
| dc.description.abstract | Purpose of Review: The success and failure of therapeutic antibodies against SARS-CoV-2 offer a lesson on therapeutic antibody design and development. Recent Findings: Therapeutic antibody against SARS-CoV-2 facing challenging antibody escape mutation. A paratope design strategy targeting pancoronavirus conserved epitope(s) and combining two antibodies as antibody cocktails or bispecific antibodies may overcome antibody escape mutations of the SARS-CoV-2 spike. Instead of designing broadly neutralizing antibodies, repurposing antibodies can target viral or host molecules to inhibit the virus and alleviate dysregulation of the host immune response. Summary: Detailed strategies for engineering therapeutic antibodies, including antibody format, are reviewed in this article. | |
| dc.identifier.citation | Current Clinical Microbiology Reports (2023) | |
| dc.identifier.doi | 10.1007/s40588-023-00212-7 | |
| dc.identifier.eissn | 21965471 | |
| dc.identifier.scopus | 2-s2.0-85176471980 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/91113 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Engineered Therapeutic Antibody Against SARS-CoV-2 | |
| dc.type | Review | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85176471980&origin=inward | |
| oaire.citation.title | Current Clinical Microbiology Reports | |
| oairecerif.author.affiliation | Siriraj Hospital |